Journal of Hepatology
Volume 56, Issue 2 , Pages 348-354 , February 2012

Midodrine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study

  • Virendra Singh

      Affiliations

    • Department of Hepatology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
    • Corresponding Author InformationCorresponding author. Address: Professor, Department of Hepatology, PGIMER, Chandigarh 160 012, India. Fax: +91 172 2744401.
    • ,
  • Sahdeb P. Dhungana

      Affiliations

    • Department of Internal Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India
    • ,
  • Baljinder Singh

      Affiliations

    • Department of Nuclear Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India
    • ,
  • Rajesh Vijayverghia

      Affiliations

    • Department of Cardiology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
    • ,
  • Chander K. Nain

      Affiliations

    • Department of Gastroenterology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
    • ,
  • Navneet Sharma

      Affiliations

    • Department of Internal Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India
    • ,
  • Ashish Bhalla

      Affiliations

    • Department of Internal Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India
    • ,
  • Pramod K. Gupta

      Affiliations

    • Department of Biostatistics, Postgraduate Institute of Medical Education & Research, Chandigarh, India

Received 20 December 2010 ,Revised 6 April 2011 ,Accepted 24 April 2011.

References 

  1. Bories P, Garcia-Compean D, Michel H, Bourel M, Capron JP, Gauthier A, et al. The treatment of refractory ascites by the LeVeen shunt: a multi centre controlled trial (57 patients). J Hepatol. 1986;3:212–218
  2. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151–1157
  3. Gines P, Cardeenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl Med. 2004;350:1646–1654
  4. Cardenas A, Arroyo V. Mechanism of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinal Metab. 2003;17:607–622
  5. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology. 1998;27:264–272
  6. Runyon BA. Ascites and spontaneous bacterial peritonitis. In:  Feldman M,  Friedman LS,  Sleisenger MH editor. Sleinger and Fordtrans’s gastrointestinal and liver disease. 7th ed.. Philadelphia: Saunders; 2002;p. 1517–1542
  7. Stanley MM, Ochi S, Lee KK, Nemchausky BA, Greenlee HB, Allen JI, et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N Engl J Med. 1989;321:1632–1638
  8. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med. 2000;342:1701–1707
  9. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Ruiz del Arbol L, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis and albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123:1839–1847
  10. Moreau R, Durand F, Poynard T, Duhamel C, Jean P, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicentre study. Gastroenterology. 2002;122:923–930
  11. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las HD, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36:941–948
  12. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 2000;33:43–48
  13. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot Thoraval F, et al. Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology. 2002;36:374–380
  14. Moreau R, Asselah T, Caudat B, De Kerguenec C, Pessione F, Bernard B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomized pilot study. Gut. 2002;50:90–94
  15. Singh V, Kumar R, Nain CK, Singh B, Sharma N, Bhalla A, et al. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med. 2006;260:62–68
  16. Singh V, Kumar R, Nain CK, Singh B, Sharma AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized controlled trial. J Gastroenterol Hepatol. 2006;21:303–307
  17. Singh V, Dheerendra PC, Singh B, Nain CK, Chawla D, Sharma N, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol. 2008;103:1399–1405
  18. Appenrodt B, Wolf A, Grunhage F, Trebicka J, Schepke M, Rabe C, et al. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs. albumin. A randomized pilot study. Liver Int. 2008;28:1019–1025
  19. Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Pappas C, Katsaraki A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol. 2005;100:879–885
  20. Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsinos EV. Effects of a 7 day treatment with midodrine in nonazotemic cirrhotic patients with and without ascites. J Hepatol. 2007;46:213–221
  21. Krag A, Moller S, Henriksen JH, Niels-Henrik HR, Finn L. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology. 2007;46:1863–1871
  22. Tandon P, Tsuyuki RT, Mitchell L, Hoskinson M, Ma MM, Wong WW, et al. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int. 2009;29:169–174
  23. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23:164–176
  24. Ruiz-Del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology. 1997;113:579–586
  25. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38:258–266
  26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  27. Kupari M, Koskinen P. Systolic flow velocity profile in the left ventricular outflow tract in persons free of heart disease. Am J Cardiol. 1993;72:1172–1178
  28. Cardenas A, Gines P. Management of hyponatremia in cirrhosis. Ascites and renal dysfunction in liver disease. 2nd ed.. Oxford: Blackwell Publishing; 2005;p. 315–340
  29. McTavish D, Goa KL. Midodrine: a review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs. 1989;38:757–777
  30. Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology. 1998;28:937–943
  31. Gines P, Tito LI, Arroyo V, Planas R, Panes J, Viver J, et al. Randomised comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94:1493–1502
  32. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690–1697

PII: S0168-8278(11)00522-8

doi: 10.1016/j.jhep.2011.04.027

Journal of Hepatology
Volume 56, Issue 2 , Pages 348-354 , February 2012

Article Tools

* Image Usage & Resolution